Introduction
Numerous perturbations of B-cell phenotype and function have been described in HIV-infected individuals (reviewed 1, 2 ). Phenotypic perturbations of B cells circulating in the peripheral blood include over-representation of activated, exhausted, and terminally differentiated B cells associated with HIV viremia [3] [4] [5] ; over-representation of immature/transitional B cells associated with HIV-induced CD4 + T-cell lymphopenia 6, 7 ; and reduced representation of CD27 + memory B cells associated with most stages of HIV infection [8] [9] [10] [11] [12] [13] . Most of these studies, whether longitudinal or cross-sectional, have been conducted on chronically HIV-infected individuals,
whereas only a few studies, generally with small sample sizes, have addressed the effect of duration of infection and initiation of antiretroviral therapy (ART) on perturbations of B-cell subpopulations in HIV-infected individuals 9, 14, 15 .
Functional perturbations of B cells in HIV-infected individuals include
hypergammaglobulinemia associated with polyclonal and HIV-specific activation of B cells induced by ongoing HIV replication 15, 16 , as well as decreased B-cell responses to specific immunogens and non-HIV pathogens 11, 17, 18 . The latter is likely a reflection of both CD4 + T-cell dependent and independent defects in B cells that arise in HIV-infected individuals, and especially in individuals with ongoing viral replication. Many of the functional B-cell defects described in HIV-viremic individuals can be improved with ART, although there is one important exception that has received relatively little attention. While B-cell responses against non-HIV antigens are either stabilized or increased following initiation of ART [19] [20] [21] [22] , the reverse is often observed for B-cell responses against HIV antigens 15, 23, 24 , suggesting that the humoral 4 response against HIV is dependent on continuous HIV replication. In the most comprehensive study on B-cell responses following ART, Morris and colleagues described a rapid loss of HIVspecific B cells (actively secreting plasmablasts) during therapy, followed by a more gradual decrease in antibody titers against HIV in chronically infected individuals; the loss was even more rapid in early-treated individuals 15 .
In a previous study of chronically HIV-infected individuals, we reported a reduction in Bcell numbers and the presence of perturbed B-cell subpopulations prior to initiation of ART followed by partial normalization one year after successful reduction in viremia by ART 25 . In a more recent study 5 , we identified a subpopulation of CD27 -tissue-like memory B cells within an abnormal CD21 lo B-cell compartment of the peripheral blood of chronically HIV-viremic individuals; this subpopulation had been included within the activated B-cell compartment that we had previously described 25 . These CD27 -tissue-like memory B cells bore many features of exhausted cells, arising in the context of chronic immune activation, and with features that include expression of multiple inhibitory receptors, a stunted replication history and immunoglobulin diversification, as well as a reduced capacity to proliferate 25 . In addition, there was an enrichment of the HIV-specific response within this compartment of tissue-like memory B cells whereas B-cell responses to the recall antigen influenza were enriched within the classic CD27 + memory B-cell compartment. Similar features have been described for both B cells and T cells in the context of persisting pathogens, including HIV, LCMV, HCV, and malaria [26] [27] [28] .
In the present study, we have extended both our previous studies to investigate the phenotypic profile of B cells as well as B-cell function in early and chronic HIV infected individuals and to evaluate the longitudinal effects of ART in such individuals. We identified clear differences in these parameters between individuals during early versus chronic HIV 5 infection, and both prior to and one year after initiation of ART. These findings provide new insight into the pathogenesis of B cell abnormalities in HIV infection and provide further evidence that early initiation of ART may help preserve immune capacity.
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Methods
Study participants
Leukapheresis and blood draw products were obtained from HIV-infected and HIV-uninfected individuals following informed consent approved by the Institutional Review Board of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) in accordance with the Declaration of Helsinki. Three groups of individuals were recruited as detailed in Table 1 . Early HIV-infected individuals were defined as having been infected with HIV within 6 months of donating baseline samples. Chronically HIV-infected individuals were defined as having been infected for at least 6 months and usually for several years. HIV plasma viremia was measured by branched DNA assay (Bayer Diagnostics, Berkeley, CA), with a lower limit of detection of 50 copies per ml. Functional B cell assays were performed on a subset of individuals who received seasonal influenza vaccination on a regular annual basis.
Phenotypic analyses
Multi-color flow cytometry analyses were performed on whole blood to determine lymphocyte counts and the frequency of each B-cell subpopulation. Lymphocyte counts were performed by a core NIAID facility following standard procedures. Analyses were performed on a Canto flow cytometer (BD Biosciences) with FlowJo software (Tree Star, Ashland, OR).
Functional analyses
Peripheral blood mononuclear cells (PBMCs) were obtained by density-gradient centrifugation.
Mature (CD10 -) B cells were isolated from PBMCs by negative selection using a B-cell enrichment custom cocktail containing an anti-CD10 monoclonal antibody and magnetic beadbased robotic separation (StemCell Technologies, Vancouver, BC). The purity of B cells was typically greater than 95%. Enrichment for CD27 + B cells was performed as previously described 5 , with biotinylated anti-CD27 (eBioscience) and anti-biotin Microbeads (Miltenyi Biotech, Auburn, CA). The CD27 + B cells were placed in culture for 4 days and then used to perform memory B-cell Elispot assays, as previously described 5 , with the following modifications. The Elispot assays for influenza were performed as described 29 , with the modification that IgA, IgG, and IgM isotypes were measured separately as previously described 5 . The source of seasonal influenza vaccine preparation used for coating was matched with the most recent vaccine received by each participant. The ancestral HIV-1 gp120 preparation used for direct coating (immobilized format previously described 5 ) was also the same source that was biotinylated for the soluble approach. In this case, wells were coated with 5 µg/ml each of antihuman lambda and kappa antibodies (Rockland Immunochemicals, Gilbertsville, PA) and 8 detection was made with the biotinylated HIV-1 gp120, followed by standard detection, as previously described 5 .
Statistical analyses
Three-group comparisons were performed using the Kruskall-Wallis test followed by pair wise comparisons with the Wilcoxon rank sum test, as previously described 5 . Two-group comparisons were performed using the Wilcoxon rank sum test, and the Wilcoxon signed rank test was used for comparisons within a group. Changes in lymphocyte counts following initiation of ART were analyzed as previously described using mixed models 25 . Changes in Bcell subpopulations between baseline and 12 months of ART were analyzed as previously described 25 . Briefly, percent differences before and after ART were calculated as a sum distance and a permutation test was used to evaluate whether this sum distance was significant.
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Results
Lymphocyte Counts Before and After ART
We first measured the absolute number of CD19 + B cells, as well as CD4 + and CD8 + T cells in the peripheral blood of three groups of individuals, namely ART-untreated individuals in early and chronic HIV infection, as well as HIV-uninfected control individuals (Table 1) . These analyses were restricted to men given the paucity of early HIV-infected women recruited in most North American cohorts, including ours, and strong evidence for gender-related immunologic and virologic differences in HIV infection 30, 31 . B-cell and CD4 + T-cell counts were significantly higher in HIV-negative individuals compared to both early and chronically HIV-infected individuals whereas CD8 + T-cell counts were lower in HIV-uninfected compared to both HIVinfected groups ( Figure 1 ). There was no significant difference in B-cell and CD8 + T-cell counts between the two HIV-infected groups whereas CD4 + T-cell counts were significantly higher in early compared to chronically HIV-infected individuals (P < 0.001). There was no significant difference in HIV plasma viremia between the two HIV-infected groups and no significant difference in age between the three groups (Table 1) , and differences in Figure show a more rapid normalization of CD8 + T cells in early-treated individuals 32, 33 . These data also confirm the observation made in our previous study, namely that B cells are more similar to CD4 + than to CD8 + T cells with regard to changes following initiation of ART 25 , and that B-cell and CD4 + T-cell numbers increase significantly in both early and chronically HIV-infected individuals following ART. ; these percentages were unchanged by ART (data not shown). Frequencies for each B-cell subpopulation were available on 27 early and 31 chronically HIV-infected individuals, respectively, prior to initiation of ART. As shown in Figure 3 and by P values in Table 2 were not significantly different prior to and after 12 months of ART for both groups of HIVinfected individuals, and frequencies between the two groups were not significantly different, either before or after ART (supplemental Figure 1A and 1B) . Furthermore, there were no differences in total unswitched and switched ASC frequencies, measured as previously described 15 5 , either between groups or between pre and post ART (supplemental Figure 1B for distribution and 2 for counts).
B-cell Subpopulations
In the majority of previous studies 5, 17, 23, 36 , HIV envelope-specific B cells or antibodies were detected following interaction with envelope protein that was directly immobilized on a plastic surface. In our current study, the response to immobilized HIV envelope was low in early HIV-infected individuals prior to initiation of ART and remained low after 12 months of ART ( Figure 5A ), whereas in chronically HIV-infected individuals the baseline response was higher and was significantly reduced after the same period of ART ( Figure 5B ). In contrast, when the reactivity to soluble HIV envelope was assessed using an approach similar to one recently In a previous study, we reported that the number of total B cells in the peripheral blood of chronically HIV-infected individuals increased significantly after initiation of ART, similar to the increases in CD4 + but not CD8 + T cells following initiation of ART 25 . In the present study, we extended these findings by demonstrating that the early phase of HIV infection was distinct from the chronic stage, both in terms of immunologic parameters prior to the initiation of ART and the dynamics of response following initiation of ART. With regard to the two major T-cell populations, CD4 + T-cell numbers were higher in early compared to chronically HIV-infected individuals prior to ART, whereas the abnormally high CD8 + T cell-numbers observed in both groups prior to ART were normalized more rapidly following ART in early compared to chronically HIV-infected individuals. These observations are consistent with the concept that the immune system is better able to recover when ART is initiated early in the course of HIV infection as opposed to during the chronic phase of HIV disease 32, 33 . With regard to B cells, total counts increased significantly in both groups following reduction of HIV plasma viremia as a result of initiation of ART, although there was no significant difference between the two groups. However, changes in total lymphocyte counts that occur in the peripheral blood following the reduction of HIV plasma viremia by ART are driven by poorly understood and somewhat controversial mechanisms that are likely to include redistribution of cells between tissues and blood, increased production, and replacement of short-lived activated cells with longlived cells 40, 41 . With regard to the latter mechanism, B cells of early and chronically HIVinfected individuals underwent several changes at the subpopulation level that likely had an impact on overall longevity. In both early and chronic HIV infection, the increased frequency of CD27 + activated memory B cells prior to initiation of ART was significantly reversed after ART (see Figure 3 ; 4 ). These activated B cells have previously been shown to be highly susceptible to cell death by CD95-mediated extrinsic apoptosis 42 . Furthermore, plasmablasts, a subpopulation of short-lived Ki-67 + B cells likely to be responsible for increased B-cell turnover in HIVviremic individuals 4, 9, 42 , were more abundant in early HIV-infected individuals prior to ART and normalized after ART. Finally, immature/transitional B cells, which have been shown to be highly susceptible to cell death by intrinsic apoptosis 42 , were more abundant in chronically HIV-infected individuals prior to initiation of ART and significantly depleted after ART.
Collectively, the replacement of these various short-lived B cells prior to initiation of ART with longer-lived naïve and resting memory B cells after ART in HIV-infected individuals treated during the early and chronic stages of infection may help explain the increases in B-cell numbers observed in both groups, although redistribution from tissues cannot be excluded.
Established humoral immunity is comprised of both memory B cells that can respond rapidly upon re-encounter with cognate antigen and long-lived plasma cells responsible for maintaining stable levels of antibodies 39, 43 . In HIV infection, both components of humoral immunity become perturbed soon after infection 9, 14, 15, 17 5, 44 , which are also maintained at high frequencies by HIV viremia (see Figure 3) . Finally, HIV-induced perturbation of IgM-memory B cells has been described 9, 11, 12 , and one 11 , but not the other study 12 , demonstrated an association with decreased responses to T-cell-independent antigens. However, this subpopulation remains poorly characterized and somewhat controversial 43 . Collectively, these observations illustrate the complexity of memory B cells in HIV infection and underscore the need to carefully define populations and combine phenotypic analyses with functional correlates.
In the present study, we investigated several phenotypic and functional attributes of 14 , although responses to childhood and T-cell-independent vaccines were not restored in earlytreated HIV-infected adults 17 . Nonetheless, these data provide an additional argument that early initiation of ART may help restore at least certain aspects of the humoral arm of the immune system in HIV-infected individuals.
The vast majority of studies on the humoral response against HIV envelope have focused on the serum antibody response with relatively little emphasis on HIV envelope-specific memory B cells 45 . However, memory B-cell responses are also important to consider, both for vaccine development and ability of the immune system to control HIV in infected individuals. Several studies have demonstrated that the maintenance of HIV-specific antibodies and memory B cells is dependent on the presence of HIV antigen 15, 23, 36, 46, 47 . Our findings largely confirm this observation for the majority of chronically HIV-infected individuals studied. However, we did find evidence of a stronger and more sustained memory B-cell response to soluble HIV envelope in early-treated when compared to chronically-treated individuals. Given the abundant evidence that the structure and presentation of HIV envelope are important determinants of the type of antibody response generated 48, 49 , it is not surprising to find differences in responsiveness to immobilized versus soluble forms of the same antigen shown here and reported elsewhere 37 .
Nonetheless, the significance of our observation needs to be further characterized and 
